Bulletin
Investor Alert

Market Pulse Archives

Oct. 5, 2021, 11:22 a.m. EDT

E.U. authorizes third dose of Moderna's COVID-19 vaccine for the immunocompromised

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Moderna Inc. (MRNA)
  • X
    BioNTech SE ADR (BNTX)
  • X
    Pfizer Inc. (PFE)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

Shares of Moderna Inc. /zigman2/quotes/205619834/composite MRNA -11.87% gained 1.2% in trading on Tuesday after the company announced that the European Medicines Agency authorized a third dose of its COVID-19 vaccine for people who are severely immunocompromised. The authorization applies to those who are least 12 years old who have waited at least 28 days since getting their second dose of the vaccine. The U.S. authorized a third of the Moderna and BioNTech /zigman2/quotes/214419716/composite BNTX -4.91% /Pfizer Inc. /zigman2/quotes/202877789/composite PFE +1.77% vaccines for the immunocompromised people back in August. Moderna's stock is up 216.1% so far this year, while the broader S&P 500 /zigman2/quotes/210599714/realtime SPX -1.18% has gained 14.7%.

/zigman2/quotes/205619834/composite
US : U.S.: Nasdaq
$ 310.61
-41.82 -11.87%
Volume: 21.60M
Dec. 1, 2021 4:00p
P/E Ratio
19.08
Dividend Yield
N/A
Market Cap
$142.89 billion
Rev. per Employee
$617,996
loading...
/zigman2/quotes/214419716/composite
US : U.S.: Nasdaq
$ 334.48
-17.26 -4.91%
Volume: 3.71M
Dec. 1, 2021 4:00p
P/E Ratio
9.66
Dividend Yield
N/A
Market Cap
$85.30 billion
Rev. per Employee
$283,276
loading...
/zigman2/quotes/202877789/composite
US : U.S.: NYSE
$ 54.68
+0.95 +1.77%
Volume: 59.85M
Dec. 1, 2021 4:03p
P/E Ratio
16.23
Dividend Yield
2.85%
Market Cap
$301.58 billion
Rev. per Employee
$533,860
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
4,513.04
-53.96 -1.18%
Volume: 3.04B
Dec. 1, 2021 5:04p
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.